HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Cosmetics Reform Bill Relaunches In Senate, Sending Stakeholders To Familiar Corners

This article was originally published in The Rose Sheet

Executive Summary

The Personal Care Products Safety Act introduced in the Senate May 11, and the Cosmetic Modernization Amendments Act that launched in the House earlier this year, closely mirror versions that divided big and small business in the last Congress. So while the US political environment may be dramatically changed, the legislative situation for stakeholders seeking updated cosmetics regulations, at the moment, is not.

You may also be interested in...

‘California’s A Problem,’ But Prop 65 Preemption For Cosmetics Could Be Out Of Reach

California is the poster child for regulation in excess of federal requirements, but the biggest challenges it poses to cosmetics companies will be difficult – if not impossible – to resolve via “national uniformity” provisions in legislation before Congress.

Trump's Budget Surprise: FDA Gets 13% Increase

President Trump's FY 2019 budget request includes $473m in new non-user fee revenue for the US agency, a reversal of the previous year's request.

ICMAD Beefs Up Lobbying To Deter 'Wrong Decision' In Congress

Pam Busiek, head of the Independent Cosmetic Manufacturers and Distributors, discusses the trade group's ongoing work in Washington where multiple, differently sized bills for updating cosmetics regulations are under consideration. Notably, ICMAD's roster of advocates now includes former FDA Cosmetics Director John Bailey.

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts